اخبار و اعلانات

 آمار

تعداد نشریات286
تعداد نشریات سازمان84
تعداد شماره‌ها2,848
تعداد مقالات32,322
تعداد مشاهده مقاله41,447,438
تعداد دریافت فایل اصل مقاله18,648,211
Alekhin, S. A, Firsova, T. I, Nazarenko, D. P, Bezhina, E. N, Druzhikin, L. V. (1400). Effect of Anti-TNFα Therapy by Infliximab against Pancreatic Tissue Damage in Severe Acute Necrotizing Pancreatitis. سامانه مدیریت نشریات علمی, 76(5), 1237-1244. doi: 10.22092/ari.2021.355845.1726
S. A Alekhin; T. I Firsova; D. P Nazarenko; E. N Bezhina; L. V Druzhikin. "Effect of Anti-TNFα Therapy by Infliximab against Pancreatic Tissue Damage in Severe Acute Necrotizing Pancreatitis". سامانه مدیریت نشریات علمی, 76, 5, 1400, 1237-1244. doi: 10.22092/ari.2021.355845.1726
Alekhin, S. A, Firsova, T. I, Nazarenko, D. P, Bezhina, E. N, Druzhikin, L. V. (1400). 'Effect of Anti-TNFα Therapy by Infliximab against Pancreatic Tissue Damage in Severe Acute Necrotizing Pancreatitis', سامانه مدیریت نشریات علمی, 76(5), pp. 1237-1244. doi: 10.22092/ari.2021.355845.1726
Alekhin, S. A, Firsova, T. I, Nazarenko, D. P, Bezhina, E. N, Druzhikin, L. V. Effect of Anti-TNFα Therapy by Infliximab against Pancreatic Tissue Damage in Severe Acute Necrotizing Pancreatitis. سامانه مدیریت نشریات علمی, 1400; 76(5): 1237-1244. doi: 10.22092/ari.2021.355845.1726

Effect of Anti-TNFα Therapy by Infliximab against Pancreatic Tissue Damage in Severe Acute Necrotizing Pancreatitis

Archives of Razi Institute
مقاله 12، دوره 76، شماره 5، بهمن و اسفند 2021، صفحه 1237-1244    اصل مقاله (614.76 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2021.355845.1726
نویسندگان
S. A Alekhin* ؛ T. I Firsova؛ D. P Nazarenko؛ E. N Bezhina؛ L. V Druzhikin
Belgorod State University, Pobedy St., 85, Belgorod, 308015, Russia
چکیده
Nowadays, it is difficult to find a more complicated inflammatory disease of the abdominal organs in its pathogenesis than acute pancreatitis (AP). The application of antimediatory drugs and antimetabolites is the most promising direction in the correction of inflammatory pathological processes. The study of possible applications of a new group of drugs (monoclonal antibodies) that may trigger inflammation is also of great interest. The present study aimed to study the effect of infliximab on the lethality, volume, and nature of pancreatic lesions in severe necrotizing ductal pancreatic necrosis. The study was conducted on female Wistar rats (n=30) of similar age in the weight range of 200-250g. All manipulations were performed under general anesthesia by intraperitoneal injection of zoletil at a dose of 60 mg/kg, as well as chloral hydrate at a dose of 125 mg/kg. Model of severe acute necrotizing pancreatitis was performed through the injection of 0.5 ml of a buffer solution containing a bile acid salt-sodium taurocholate introductory. The animals were divided into the following groups: Group A (n=6): normal values; Group B (n=6): the mortality study was conducted in acute destructive pancreatitis in a period of 24 h; Group C (n=6): the simulation of acute severe necrotic pancreatitis was performed in this group along with the study of the volume of pancreatic lesions for a period of 6 h from the moment of modeling; Group D (n=6): in this group, the effect of infliximab (at a dose of 60 mkg/kg) was studied on mortality in severe destructive pancreatitis for a period of 24 h from the moment of modeling; Group E (n=6): in this group, the effect of infliximab (at a dose of 120 mkg/kg) was studied on the volume of pancreatic lesions in severe destructive pancreatitis for a period of 6 h from the moment of modeling. During the assessment of pancreatic damage, the mean±SD volume of pancreatic lesions was determined to be 34.8%±1.2% in a period of 6 h after modeling. Assessment of pancreatic damage in group E and the protective effect of infliximab at a dose of 60 mg/kg showed that the total volume of the necrotic pancreatic lesion was determined to be 21.3%±1.4% after a period of 6 h from the moment of AP modeling. In the course of this study, it was revealed that the application of infliximab at a dose of 60 mcg/kg led to a pronounced positive effect on the pancreatic lesion, manifested by up to 50% decrease in mortality for one day in group D. Infliximab had a definite protective effect in AP, decreasing the volume of the injury, as well as the mortality rate by half for 24 h. Therapy with anti-tumor necrosis factor with infliximab could significantly reduce the volume of pancreatic lesions in severe forms of pancreatic necrosis, which contributed to a pronounced decrease in mortality for 1 day from the moment of pathology reproduction.
کلیدواژه‌ها
Infliximab؛ Severe acute necrotizing pancreatitis؛ pancreatic damage
سایر فایل های مرتبط با مقاله
مراجع
  1. Goodchild G, Chouhan M, Johnson GJ. Practical guide to the management of acute pancreatitis. Frontline Gastroenterol. 2019;10(3):292-9.
  2. Anderson MC, Bergan JJ. Significance of vascular injury as a factor in the pathogenesis of pancreatitis. Ann Surg. 1961;154:58-67.
  3. Firsova TI AS, Bezhina EN, Lukyanchikov GF, Reznikov RM, Stepchenko AA, Lazareva GA. The degree of pancreatic edema in ischemic damage during acute pancreatitis in the conditions of pharmacological correction with infliximab. Int J Pharm Sci Res. 2020;12(1):1092-6.
  4. Hoffmann TF, Leiderer R, Waldner H, Arbogast S, Messmer K. Ischemia reperfusion of the pancreas: a new in vivo model for acute pancreatitis in rats. Res Exp Med (Berl). 1995;195(3):125-44.
  5. Goulden MR. The pain of chronic pancreatitis: a persistent clinical challenge. Br J Pain. 2013;7(1):8-22.
  6. Zerem E. Treatment of severe acute pancreatitis and its complications. World J Gastroenterol. 2014;20(38):13879-92.
  7. Takeda K. Antiproteases in the treatment of acute necrotizing pancreatitis: continuous regional arterial infusion. J Pancreas. 2007;8(4):526-32.
  8. Danilenko LM. Doxorubicin-associated Cardiomyopathy: New Approaches to Pharmacological Correction Using 3-(2,2,2-trimethylhydrazinium) Propionate Derivatives. Res. Results Pharmacol. 2018;4(1):81-6.
  9. Kalmykov VA, Kusov PA, Yablonskaia MI, Korshunov EN, Korshunova DS, Kubekina MV, et al. New personalized genetic mouse model of Lesch-Nyhan syndrome for pharmacology and gene therapy. Res Results Pharmacol. 2018;4(4):115-22.
  10. Kazbekovna BS FK, Vitalevich VD, Phillipovich SK. Pleyotropic antiaggregant effects of an innovative antiarrhythmic of class III SS-68, an indole derivative. Res Results Pharmacol. 2017;3(2).
  11. Kurganov NA, Blinova EV, Semeleva EV, Gromova IA, Blinov DS, Novikov AV, et al. 2-aminoaethanesulfonic acid compounds possess protective property in reperfusion-induced heart jnjury. Kazbekovna BS FK, Vitalevich VD, Phillipovich SK. Pleyotropic antiaggregant effects of an innovative antiarrhythmic of class III SS-68, an indole derivative. Res Results Pharmacol. 2017;3(2). 2018;4(2):19-26.
  12. Shulginova AA, Konoplya AI, Bystrova NA. Disorders of the immune status in patients with chronic cerebral ischemia; differentiated pharmacological correction. Kazbekovna BS FK, Vitalevich VD, Phillipovich SK. Pleyotropic antiaggregant effects of an innovative antiarrhythmic of class III SS-68, an indole derivative. Res Results Pharmacol. 2017;3(2). 2018;4(2):105-23.
  13. Voronkov AV, Pozdnyakov DI. Endothelotropic activity of 4-hydroxy-3,5-di-tret-butylcinnamic acid in the conditions of experimental cerebral ischemia. Kazbekovna BS FK, Vitalevich VD, Phillipovich SK. Pleyotropic antiaggregant effects of an innovative antiarrhythmic of class III SS-68, an indole derivative. Res Results Pharmacol. 2018;4(2):1-10.
  14. Avdeeva NV, Sidorova SA, Gudyrev OS, Osipova OgA, Golubev IV. Mechanism of neuroprotective effect of mGluR4 agonists. Kazbekovna BS FK, Vitalevich VD, Phillipovich SK. Pleyotropic antiaggregant effects of an innovative antiarrhythmic of class III SS-68, an indole derivative. Res Results Pharmacol. 2017;3(2). 2019;5(2):43-7.
  15. Korokin M, Gureev V, Gudyrev O, Golubev I, Korokina L, Peresypkina A, et al. Erythropoietin Mimetic Peptide (pHBSP) Corrects Endothelial Dysfunction in a Rat Model of Preeclampsia. Int J Mol Sci. 2020;21(18).
  16. Palikov VA, Palikova YA, Borozdina NA, Nesmeyanova EN, Rudenko PA, Kazakov VA, et al. A novel view of the problem of Osteoarthritis in experimental rat model. Kazbekovna BS FK, Vitalevich VD, Phillipovich SK. Pleyotropic antiaggregant effects of an innovative antiarrhythmic of class III SS-68, an indole derivative. Res Results Pharmacol. 2017;3(2). 2020;6(2):19-25.
  17. Stupakova EG, Lazareva GA, Gureev VV. Correction of morphofunctional disturbances arising when modelling Preeclampsia with resveratrol and nicorandil. Kazbekovna BS FK, Vitalevich VD, Phillipovich SK. Pleyotropic antiaggregant effects of an innovative antiarrhythmic of class III SS-68, an indole derivative. Res Results Pharmacol. 2017;3(2). 2018;4(1):59-71.
  18. Norman JG, Fink GW, Franz MG. Acute pancreatitis induces intrapancreatic tumor necrosis factor gene expression. Arch Surg. 1995;130(9):966-70.
  19. Zhang G, Zhang Z, Liu X, Yan L, Hu W, Tian B, et al. Intrapulmonary expression of tumor necrosis factor alpha mRNA and its significance in rats with acute pancreatitis. J West China Univ Med Sci. 1999;30(4):379-83.
  20. Tekin SO, Teksoz S, Terzioglu D, Arikan AE, Ozcevik H, Uslu E. Use of infliximab in treatment of acute pancreatitis. Bratisl Lek Listy. 2015;116(3):167-72.
  21. Prado MS, Bendtzen K, Andrade LEC. Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events. Expert Opin Drug Metab Toxicol. 2017;13(9):985-95.
  22. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum. 2004;50(4):1270-6.
  23. Wong U, Cross RK. Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease. Expert Opin Investig Drugs. 2019;28(5):473-9.
  24. Toupin-April K, Barton J, Fraenkel L, Li LC, Brooks P, De Wit M, et al. Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting. J Rheumatol. 2017;44(10):1544-50.
  25. Wang XY, Tang QQ, Zhang JL, Fang MY, Li YX. Effect of SB203580 on pathologic change of pancreatic tissue and expression of TNF-α and IL-1β in rats with severe acute pancreatitis. Eur Rev Med Pharmacol Sci. 2014;18(3):338-43.
  26. Malleo G, Mazzon E, Siriwardena AK, Cuzzocrea S. TNF-alpha as a therapeutic target in acute pancreatitis--lessons from experimental models. Sci World J. 2007;7:431-48.
  27. Pandol SJ PS, Gukovsky I, Zaninovic V, Jung Y, Zong Y, Solomon TE, Gukovskaya AS, Tsukamoto H. Ethanol diet increases the sensitivity of rats to pancreatitis induced by cholecystokinin octapeptide. Gastroenterology. 1999;117(3):706-16.
  28. Li R, Song J, Wu W, Wu X, Su M. Puerarin exerts the protective effect against chemical induced dysmetabolism in rats. Gene. 2016;595(2):168-74.
  29. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood. 2004;104(3):649-54.
  30. Malleo G, Mazzon E, Siriwardena AK, Cuzzocrea S. Role of tumor necrosis factor-alpha in acute pancreatitis: from biological basis to clinical evidence. Shock. 2007;28(2):130-40.
  31. Murugesan SR, King CR, Osborn R, Fairweather WR, O'Reilly EM, Thornton MO, et al. Combination of human tumor necrosis factor-alpha (hTNF-alpha) gene delivery with gemcitabine is effective in models of pancreatic cancer. Cancer Gene Ther. 2009;16(11):841-7.
  32. Hoeben D, Burvenich C, Trevisi E, Bertoni G, Hamann J, Bruckmaier RM, et al. Role of endotoxin and TNF-alpha in the pathogenesis of experimentally induced coliform mastitis in periparturient cows. J Dairy Res. 2000;67(4):503-14.
  33. Oruc N, Ozutemiz AO, Yukselen V, Nart D, Celik HA, Yuce G, et al. Infliximab: a new therapeutic agent in acute pancreatitis? Pancreas. 2004;28(1):e1-8.
  34. Genovese T, Mazzon E, Di Paola R, Muia C, Crisafulli C, Menegazzi M, et al. Hypericum perforatum attenuates the development of cerulein-induced acute pancreatitis in mice. Shock. 2006;25(2):161-7.
  35. Sanfey H, Bulkley GB, Cameron JL. The pathogenesis of acute pancreatitis. The source and role of oxygen-derived free radicals in three different experimental models. Ann Surg. 1985;201(5):633-9.
آمار
تعداد مشاهده مقاله: 1,499
تعداد دریافت فایل اصل مقاله: 508


counter
سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب